CLINICAL_TRIALS
trial_result
· 2017-01-19
Clinical Trial Update: Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia [Phase 2]
Summary
Phase 2 trial evaluating denileukin diftitox in fludarabine-refractory B-cell chronic lymphocytic leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Wake Forest University Health Sciences | Conditions: Leukemia | Phase 2 | Status: COMPLETED